Perspectum Secures $36 Million in Series C Funding Led by Oppenheimer Holdings

Perspectum, a precision health company specialising in medical imaging tools for diagnosing metabolic diseases and cancer, has recently completed the first phase of its Series C funding, securing an impressive $36 million investment. Led by Oppenheimer Holdings, this funding marks a significant milestone in Perspectum's journey, bringing its total raised capital to approximately $120 million.
‍

A key focus for Perspectum has been the development of LiverMultiScan, its flagship diagnostic tool aimed at assessing and monitoring chronic liver disease. With coverage extending to over 77 million US adults through Medicare and commercial plans, LiverMultiScan has gained significant traction in major US hospitals. The company's collaboration with Nuance, a Microsoft company, further underscores its commitment to expanding its reach and customer base.
‍

"We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies," remarked Rajarshi Banerjee, MD, PhD, CEO of Perspectum. "This new funding will help us to continue innovating new products that will make healthcare safer by providing non-invasive alternatives to biopsy."
‍

Perspectum's innovative software enhances the capabilities of standard MRI machines, allowing for the capture of multi parametric mapping data. This data, coupled with AI-driven software, enables the precise measurement of organ inflammation, aiding in both diagnosis and patient monitoring for chronic diseases.
‍

Robert Lowenthal, President of Oppenheimer Holdings, emphasised Perspectum's disruptive potential in revolutionising patient care. "Perspectum is a truly disruptive company with medical imaging software that can dramatically improve the standard of care for millions of patients," he noted.
‍

In addition to scaling its US operations, Perspectum plans to utilize the new funding to accelerate the development of its product pipeline, particularly in the areas of multi-organ inflammatory conditions and oncology. Catherine Lewis La Torre, CEO of British Patient Capital, expressed enthusiasm for Perspectum's contributions to the UK's innovation economy, highlighting the company's alignment with the Future Fund: Breakthrough program.
‍

Perspectum's achievements have garnered international attention, with its recent Series C funding round attracting investors from various regions. With offices in the US, UK, Portugal, and Singapore, Perspectum remains committed to delivering leading digital technologies that empower clinicians and improve patient outcomes.
‍

The company's commitment to precision medicine, coupled with its diverse team of experts spanning medical, scientific, and technological fields, positions Perspectum as a frontrunner in the realm of healthcare innovation. As it continues to expand its product offerings and global presence, Perspectum is poised to make significant contributions to the future of medical imaging and patient care.